DelveInsight’s “Essential Tremor Pipeline Insight 2024,” report provides comprehensive insights about 7+ companies and 10+ pipeline drugs in the Essential Tremor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Essential Tremor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Essential Tremor Overview
Essential tremor is a chronic, progressive neurological condition characterized by a 4–12-Hz kinetic tremor. This tremor occurs during voluntary movements such as writing or eating and primarily affects the hands and arms, but can eventually extend to involve other parts of the body including the head (neck), voice, jaw, and other regions.
Due to variability in causes, clinical presentation, response to medication, and pathological findings, there is growing support for the idea that ET may represent a spectrum of diseases united by the common feature of kinetic tremor in the arms. Therefore, it may be more fitting to refer to these conditions collectively as “the essential tremors.
Essential Tremor Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Essential Tremor and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Essential Tremor market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for a detailed sample report @ https://www.delveinsight.com/sample-request/essential-tremor-pipeline-insight
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Essential tremor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intranasal
Intrathecal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular
Transdermal
Molecule Type
The report covers the pipeline products that have been categorized under various Molecule types, such as
Antisense oligonucleotide
Gene therapy
Hormones
Neuropeptides
Oligonucleotides
Small Molecule
Triglyceride
Learn How the Ongoing Clinical & Commercial Activities will Affect the Essential Tremor Therapeutic Segment @ https://www.delveinsight.com/sample-request/essential-tremor-pipeline-insight
Essential Tremor Therapeutics Landscape
Key companies such as Sage therapeutics are leading the essential tremor therapeutics market with its Essential tremor drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Essential Tremor Therapeutics Market Include:
Merz Pharma
SAGE Therapeutics
GE Healthcare
Praxis Precision Medicines
OB Pharmaceuticals
Novartis
Jazz Pharmaceuticals
Essential Tremor Drugs Profile:
SAGE-324: Sage Therapeutics
SAGE-324 is a new oral investigational drug categorized as a neuroactive steroid (NAS) and a positive allosteric modulator (PAM) of GABAA receptors. NAS GABAA receptor PAMs interact with both synaptic and extrasynaptic GABAA receptors, thereby enhancing the inhibitory effects of the GABAergic system, which is crucial for regulating neuronal activity in the brain. GABA serves as the principal inhibitory neurotransmitter in the central nervous system and is essential for maintaining balanced neuronal function. Dysregulation of GABA has been implicated in the pathophysiology of ET. SAGE-324 is currently undergoing Phase II development trials.
Table of Contents
1. Report Introduction
2. Executive Summary
3. Essential Tremor Current Treatment Patterns
4. Essential Tremor – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Essential Tremor Late Stage Products (Phase-III)
7. Essential Tremor Mid-Stage Products (Phase-II)
8. Essential Tremor Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Essential Tremor Discontinued Products
13. Essential Tremor Product Profiles
14. Key Companies in the Essential Tremor Market
15. Key Products in the Essential Tremor Therapeutics Segment
16. Dormant and Discontinued Products
17. Essential Tremor Unmet Needs
18. Essential Tremor Future Perspectives
19. Essential Tremor Analyst Review
20. Appendix
21. Report Methodology
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
